

# ***DONNA J. BROGAN LECTURE IN BIostatISTICS***

Jointly Sponsored by:

The Department of Biostatistics and Bioinformatics  
&



**PRESENTED BY:**



David Oakes, Ph.D.

Department of Biostatistics and Computational Biology  
University of Rochester

## **On Some Controversies in Cardiovascular Clinical Trials**

I will address some controversies in the design and interpretation of cardiovascular clinical trials. These include the choice of primary outcome measure, the use of composite outcome measures, and the interpretation of statistical interactions – or lack of them. The talk will be illustrated by examples from my experience in the design, conduct and monitoring of clinical trials and of serving on FDA Advisory panels, most recently on the panel which recommended extension of the indication for liraglutide (“Victoza”), to include reduction of cardiovascular risk as well as improvement in glycemic control in patients with type 2 diabetes mellitus.

**Monday, April 9, 2018  
4:00 PM**

**Lawrence P. & Ann Estes Klamon Room, 8030  
Rollins School of Public Health  
Claudia Nance Rollins Building, 8<sup>th</sup> Floor  
1518 Clifton Road, N.E.**

**(Reception immediately following the lecture)**

<https://www.sph.emory.edu/departments/bios/calendar/brogan-lecture/index.html>